Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)
Phase of Trial: Phase III
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Vortioxetine (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Lundbeck A/S
- 22 Feb 2017 Planned End Date changed from 18 Sep 2018 to 1 Oct 2018.
- 06 Jun 2016 Status changed from not yet recruiting to recruiting.
- 09 Mar 2016 New trial record